Kairos Pharma, LTD. Contracts & Agreements

Purchase Agreement, dated November 12, 2024, by and between Kairos Pharma, Ltd. and Helena Global Investment Opportunities I Ltd (Filed With SEC on November 14, 2024)

Second Conversion Agreement, dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Filed With SEC on November 14, 2024)

Third Amendment to Exclusive License Agreement (Cancer Autoimmune), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Filed With SEC on November 14, 2024)

Fourth Amendment to Exclusive License Agreement (Depletion of DNA), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center and Enviro... (Filed With SEC on November 14, 2024)

Third Amendment to Exclusive License Agreement (Fibrosis), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Filed With SEC on November 14, 2024)

Third Amendment to Exclusive License Agreement (RelA of NF-kB), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Filed With SEC on November 14, 2024)

Fourth Amendment to Exclusive License Agreement (Sensitization of Solid Tumors), dated November 13, 2024, by and between Enviro Therapeutics Inc. and Cedars-Sinai Medical Center (Filed With SEC on November 14, 2024)

Form of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Doug Samuelson (Filed With SEC on November 14, 2024)

Form of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Dr. Ramachandran Murali (Filed With SEC on November 14, 2024)

Form of the Amendment No.1 to the Employment Agreement by and between Kairos Pharma, Ltd and Dr. Neil Bhowmick (Filed With SEC on November 14, 2024)

Form of Amendment No. 1 to Employment Agreement by and between Kairos Pharma, Ltd. and John S. Yu (Filed With SEC on November 14, 2024)

Consulting Agreement, dated October 1, 2024, between Kairos Pharma, Ltd., Cross Current Capital LLC and Alan Masley (Filed With SEC on October 4, 2024)

Form of Advertising Services Agreement, dated September 23, 2024, between the Company and CEO.CA Technologies, Inc (Filed With SEC on September 27, 2024)

Form of Advisory & Consulting Agreement, dated September 23, 2024, between the Company and Belair Capital Advisors Inc (Filed With SEC on September 27, 2024)

Bioassay Services Agreement between the Company and PreCheck, dated September 20, 2024 (Filed With SEC on September 24, 2024)

Underwriting Agreement between Kairos Pharma, Ltd. and Boustead Securities, LLC dated September 16, 2024 (Filed With SEC on September 17, 2024)

Common Stock Purchase Warrant issued to Boustead Securities, LLC, dated September 17, 2024 (Filed With SEC on September 17, 2024)

Common Stock Purchase Warrant issued to EF Hutton LLC, dated September 17, 2024 (Filed With SEC on September 17, 2024)

Master Services Agreement, dated August 1, 2024, between Kairos Pharma Limited and Prevail InfoWorks, Inc (Filed With SEC on August 16, 2024)

Amendment to Loan Agreement, dated August 16, 2024, between the Company and John S. Yu (Filed With SEC on August 16, 2024)

Amendment to Loan Agreement, dated August 16, 2024, between the Company and Doug Samuelson (Filed With SEC on August 16, 2024)

Amendment to Laon Agreement, dated August 16, 2024, between the Company and Neil Bhowmick (Filed With SEC on August 16, 2024)

Form of Underwriting Agreement by and between Kairos Pharma, Ltd. and Boustead Securities, LLC, as representative of the underwriters (Filed With SEC on May 1, 2024)

Form of Representatives Warrant (Filed With SEC on May 1, 2024)

Conversion Agreement, dated March 7, 2024, between Cedars-Sinai Medical Center, Kairos Pharma, Ltd. and Enviro Therapeutics, Inc (Filed With SEC on May 1, 2024)

Second Amendment to the Exclusive License Agreement to Methods and Use of Compounds that Bind to RelA of NF-kB, dated March 7, 2024, between Kairos Pharma Ltd. and Cedars-Sinai... (Filed With SEC on May 1, 2024)

Second Amendment to the Exclusive License Agreement to Composition and Methods for Treating Fibrosis with Kairos Pharma Ltd, dated March 7, 2024, between Kairos Pharma, Ltd. and... (Filed With SEC on May 1, 2024)

Second Amendment to the Exclusive License Agreement to Compositions and Methods for Treating Cancer and Autoimmune Diseases, dated March 7, 2024, between Kairos Pharma, Ltd. and... (Filed With SEC on May 1, 2024)

Third Amendment to Exclusive License to Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA, dated March 7, 2024, between... (Filed With SEC on May 1, 2024)

Third Amendment to the Exclusive License Agreement to Sensitization of Tumors to Therapies Through Endoglin Antoganism, dated March 7, 2024, between Enviro Therapeutics, Inc. and... (Filed With SEC on May 1, 2024)

Form of Loan Agreement, dated April 26, 2024, between the Company and Certain Officers (Filed With SEC on May 1, 2024)

Agreement of Merger between Kairos Pharma, Ltd. and AcTcell Biopharma, Inc. dated November 13, 2019 (Filed With SEC on September 29, 2023)

Share Exchange Agreement between Kairos Pharma, Ltd. and Enviro Therapeutics, Inc. dated June 3, 2021 (Filed With SEC on September 29, 2023)

Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated March 16, 2020 (re Depletion of Mitochondrial DNA) (Filed With SEC on September 29, 2023)

Amendment to Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated January 11, 2021 (re Depletion of Mitochondrial DNA) (Filed With SEC on September 29, 2023)

Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated March 16, 2020 (re Sensitization of Solid Tumors) (Filed With SEC on September 29, 2023)

Amendment to Exclusive Option Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated January 9, 2021 (re Sensitization of Solid Tumors) (Filed With SEC on September 29, 2023)

Exclusive License Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated June 21, 2021 (re Compositions and Methods for Treating Diseases and Conditions... (Filed With SEC on September 29, 2023)

Exclusive License Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated June 2, 2021 (re Sensitization of Tumors to Therapies Through Endoglin... (Filed With SEC on September 29, 2023)

Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (as successor to AcTcell Biopharma, Inc.) dated August 30, 2019 (re Methods of generating... (Filed With SEC on September 29, 2023)

Amendment to Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated June 17, 2021 (re Methods of generating activated T cells for cancer... (Filed With SEC on September 29, 2023)

Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated October 1, 2017 (re Methods of use of compounds that bind to RelA of NFkB) (Filed With SEC on September 29, 2023)

Amendment to Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated June 17, 2021 (re Methods of use of compounds that bind to RelA of NFkB) (Filed With SEC on September 29, 2023)

Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated October 1, 2017 (re Composition and Methods for Treating Fibrosis) (Filed With SEC on September 29, 2023)

Amendment to Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated June 17, 2021 (re Composition and Methods for Treating Fibrosis) (Filed With SEC on September 29, 2023)

Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated March 12, 2019 (re Composition and Methods for Treating Cancer and Autoimmune... (Filed With SEC on September 29, 2023)

Amendment to Exclusive License Agreement between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. dated June 17, 2021 (re Composition and Methods for Treating Cancer and... (Filed With SEC on September 29, 2023)

License and Supply Agreement between Tracon Pharmaceuticals, Inc., Enviro Therapeutics, Inc., and Kairos Pharma, Ltd. dated May 21, 2021 (Filed With SEC on September 29, 2023)

First Amendment to Exclusive License Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated April 18, 2022 (Filed With SEC on September 29, 2023)

Second Amendment to Exclusive License Agreement between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. dated October 11, 2022 (Filed With SEC on September 29, 2023)

Form of Subscription Agreement for 6% Convertible Notes (Filed With SEC on September 29, 2023)

Form of 6% Convertible Note (Filed With SEC on September 29, 2023)

Form of Investor Rights and Lock-Up Agreement for 6% Convertible Notes (Filed With SEC on September 29, 2023)

Kairos Pharma, Ltd. 2023 Equity Incentive Plan (Filed With SEC on September 29, 2023)

Form of Director Offer Letter (Filed With SEC on September 29, 2023)

Form of Employment Agreement for John Yu (Filed With SEC on September 29, 2023)

Form of Employment Agreement with Doug Samuelson (Filed With SEC on September 29, 2023)

Form of Employment Agreement for Neil Bhowmick (Filed With SEC on September 29, 2023)

Form of Employment Agreement for Ramachandran Murali (Filed With SEC on September 29, 2023)

Form of Indemnification Agreement between Kairos Pharma, Ltd. and each of its directors (Filed With SEC on September 29, 2023)

Category

Industry

Companies

Contracts

Kairos Pharma, LTD. Contracts & Agreements